IDH2
Thermo Fisher Scientific, Agios Pharmaceuticals to Codevelop Glioma Companion Diagnostic
Thermo will develop a test using its Oncomine Precision Assay to identify IDH1- and IDH2-positive low-grade glioma patients for treatment with Agios' vorasidenib.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.
The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.
Multi-Omic Analysis Uncovers Two Subgroups of Rare Olfactory Cancer
About a third of the basal-like subgroup harbored IDH2 R172 hotspot mutations, which have also been found in other cancer types.
The researchers aim to offer the half-hour diagnostic assay for use during neurosurgery to help clinicians pursue the best treatment for patients with gliomas.